Literature DB >> 15015581

The inhibitory effects of gossypol on human prostate cancer cells-PC3 are associated with transforming growth factor beta1 (TGFbeta1) signal transduction pathway.

Jiahua Jiang1, Yasuro Sugimoto, Suling Liu, Hsiang-Lin Chang, Kah-Young Park, Samuel K Kulp, Young C Lin.   

Abstract

BACKGROUND: Racemic gossypol [(+/-)-GP], a naturally occurring polyphenolic yellow pigment present in cottonseed products, inhibits in vitro proliferation of Dunning prostate cancer cells (MAT-LyLu), human prostate cancer cells derived from a bone marrow metastasis (PC3), MCF-7 and primary cultured human prostate cells. (+/-)-GP also has the ability to inhibit the metastasis of lung and lymph nodes of the androgen-independent rodent prostate cancer cell line, MAT-LyLu, after implantation into Copenhagen rats.
MATERIALS AND METHODS: The effects of (+/-)-GP on the proliferation of human prostate cancer PC3 cells were determined by thymidine incorporation assay and doubling-time (DT) determination. The mechanisms of action of (+/-)-GP on the proliferation of PC3 cells were determined by RT-PCR analysis, ELISA assay and Western blot analysis.
RESULTS: The results show that (+/-)-GP caused reductions in DNA synthesis and prolonged the DTs in PC3 cells. RT-PCR and ELISA results show that (+/-)-GP elevate the mRNA expression and protein secretion of transforming growth factor beta1 (TGFbeta1) in PC3 cells. Consistent with these findings, (+/-)-GP has been shown to decrease the cyclin D1 mRNA expression and protein expression in PC3 cells. Furthermore, the growth inhibition of PC3 cells by conditioned media collected from the (+/-)-GP-treated-PC3 cells was completely reversed by addition of 25 microg/ml of mouse monoclonal anti-TGFbeta1, -beta2, -beta3 antibody, suggesting the involvement of TGFbeta1 in (+/-)-GP-induced growth inhibition of PC3 cells.
CONCLUSION: These results indicate that the inhibitory effects of (+/-)-GP on the proliferation of human prostate cancer PC3 cells are associated with induction of TGFbeta1, which in turn influences the expression of the cell cycle-regulatory protein, cyclin D1, in prostate cancer cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15015581

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  17 in total

1.  Gossypol inhibits growth, invasiveness, and angiogenesis in human prostate cancer cells by modulating NF-κB/AP-1 dependent- and independent-signaling.

Authors:  Jiahua Jiang; Veronika Slivova; Andrej Jedinak; Daniel Sliva
Journal:  Clin Exp Metastasis       Date:  2011-12-14       Impact factor: 5.150

Review 2.  Future directions in castrate-resistant prostate cancer therapy.

Authors:  Emmanuel S Antonarakis; Michael A Carducci
Journal:  Clin Genitourin Cancer       Date:  2010-12-01       Impact factor: 2.872

3.  Apogossypolone, a novel inhibitor of antiapoptotic Bcl-2 family proteins, induces autophagy of PC-3 and LNCaP prostate cancer cells in vitro.

Authors:  Xian-Qing Zhang; Xiao-Feng Huang; Xing-Bin Hu; Yong-Hua Zhan; Qun-Xing An; Shi-Ming Yang; Ai-Jun Xia; Jing Yi; Rui Chen; Shi-Jie Mu; Dao-Cheng Wu
Journal:  Asian J Androl       Date:  2010-07-26       Impact factor: 3.285

4.  The anti-angiogenic potential of (±) gossypol in comparison to suramin.

Authors:  Gönül Ulus; A Tansu Koparal; Kemal Baysal; Günay Yetik Anacak; N Ülkü Karabay Yavaşoğlu
Journal:  Cytotechnology       Date:  2018-08-19       Impact factor: 2.058

5.  Inhibition of proliferation of prostate cancer cell line, PC-3, in vitro and in vivo using (-)-gossypol.

Authors:  Xian-Qing Zhang; Xiao-Feng Huang; Shi-Jie Mu; Qun-Xing An; Ai-Jun Xia; Rui Chen; Dao-Cheng Wu
Journal:  Asian J Androl       Date:  2010-01-18       Impact factor: 3.285

Review 6.  Novel targeted therapeutics for metastatic castration-resistant prostate cancer.

Authors:  Emmanuel S Antonarakis; Michael A Carducci; Mario A Eisenberger
Journal:  Cancer Lett       Date:  2009-08-29       Impact factor: 8.679

7.  Gossypol induces apoptosis of multiple myeloma cells through the JUN-JNK pathway.

Authors:  Luyuan Zhang; Sinan Sun; Yumin Wang; Yongzhen Mo; Fang Xiong; Shanshan Zhang; Zhaoyang Zeng; Wei Xiong; Guiyuan Li; Hao Chen; Can Guo
Journal:  Am J Cancer Res       Date:  2020-03-01       Impact factor: 6.166

8.  An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer.

Authors:  Glenn Liu; W Kevin Kelly; George Wilding; Lance Leopold; Kimberli Brill; Bradley Somer
Journal:  Clin Cancer Res       Date:  2009-04-14       Impact factor: 12.531

9.  In vivo evaluation of AT-101 (R-(-)-gossypol acetic acid) in androgen-independent growth of VCaP prostate cancer cells in combination with surgical castration.

Authors:  Robert D Loberg; Natalie McGregor; Chi Ying; Erin Sargent; Kenneth J Pienta
Journal:  Neoplasia       Date:  2007-12       Impact factor: 5.715

10.  Inhibitory activity of apogossypol in human prostate cancer in vitro and in vivo.

Authors:  Wenhua Zhan; Xingbin Hu; Jing Yi; Qunxing An; Xiaofeng Huang
Journal:  Mol Med Rep       Date:  2015-02-10       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.